Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

550 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Stepped-dose versus full-dose efavirenz for HIV infection and neuropsychiatric adverse events: a randomized trial.
Gutiérrez-Valencia A, Viciana P, Palacios R, Ruiz-Valderas R, Lozano F, Terrón A, Rivero A, López-Cortés LF; Sociedad Andaluza de Enfermedades Infecciosas. Gutiérrez-Valencia A, et al. Among authors: lozano f. Ann Intern Med. 2009 Aug 4;151(3):149-56. doi: 10.7326/0003-4819-151-3-200908040-00127. Epub 2009 Jul 6. Ann Intern Med. 2009. PMID: 19581631 Free article. Clinical Trial.
Gynaecomastia in HIV-infected men on highly active antiretroviral therapy: association with efavirenz and didanosine treatment.
Mira JA, Lozano F, Santos J, Ramayo E, Terrón A, Palacios R, León EM, Márquez M, Macías J, Fernández-Palacin A, Gómez-Mateos J, Pineda JA; Grupo Andaluz para el Estudio de las Enfermedades Infecciosas. Mira JA, et al. Among authors: lozano f. Antivir Ther. 2004 Aug;9(4):511-7. Antivir Ther. 2004. PMID: 15456082 Clinical Trial.
Efavirenz trough levels are not associated with virological failure throughout therapy with 800 mg daily and a rifampicin-containing antituberculosis regimen.
Lopez-Cortes LF, Ruiz-Valderas R, Ruiz-Morales J, Leon E, de Campos AV, Marin-Niebla A, Marquez-Solero M, Lozano F, Valiente R. Lopez-Cortes LF, et al. Among authors: lozano f. J Antimicrob Chemother. 2006 Nov;58(5):1017-23. doi: 10.1093/jac/dkl357. Epub 2006 Sep 6. J Antimicrob Chemother. 2006. PMID: 16956905 Clinical Trial.
Long-term assessment of didanosine, lamivudine, and efavirenz in antiretroviral-naive patients: 3-year follow-up.
Santos J, Palacios R, Lozano F, López M, Gálvez MC, de la Torres J, López-Cortés LF, Ríos MJ, Rivero A; Grupo Andaluz Para el Estudio de las Enfermedades Infecciosas (GAEI). Santos J, et al. Among authors: lozano f. AIDS Res Hum Retroviruses. 2008 Jan;24(1):24-6. doi: 10.1089/aid.2007.0142. AIDS Res Hum Retroviruses. 2008. PMID: 18275344 Free article. Clinical Trial.
Effectiveness and safety of didanosine, lamivudine and efavirenz versus zidovudine, lamivudine and efavirenz for the initial treatment of HIV-infected patients from the Spanish VACH cohort.
Crespo M, Ribera E, Suárez-Lozano I, Domingo P, Pedrol E, López-Aldeguer J, Muñoz A, Viladés C, Sánchez T, Viciana P, Teira R, García-Alcalde ML, Vergara A, Lozano F, Galindo MJ, Cosin J, Roca B, Terrón A, Geijo P, Vidal F, Garrido M; VACH Cohort Study Group. Crespo M, et al. Among authors: lozano f. J Antimicrob Chemother. 2009 Jan;63(1):189-96. doi: 10.1093/jac/dkn450. Epub 2008 Nov 6. J Antimicrob Chemother. 2009. PMID: 18988678 Clinical Trial.
Efficacy, safety and pharmacokinetic of once-daily boosted saquinavir (1500/100 mg) together with 2 nucleos(t)ide reverse transcriptase inhibitors in real life: a multicentre prospective study.
López-Cortés LF, Viciana P, Ruiz-Valderas R, Pasquau J, Ruiz J, Lozano F, Merino D, Vergara A, Terrón A, González L, Rivero A, Muñoz-Sanz A. López-Cortés LF, et al. Among authors: lozano f. AIDS Res Ther. 2010 Mar 17;7:5. doi: 10.1186/1742-6405-7-5. AIDS Res Ther. 2010. PMID: 20236544 Free PMC article.
Clinical and virological efficacy of etravirine plus two active Nucleos(t)ide analogs in an heterogeneous HIV-infected population.
López-Cortés LF, Viciana P, Girón-González JA, Romero-Palacios A, Márquez-Solero M, Martinez-Perez MA, López-Ruz MA, de la Torre-Lima J, Téllez-Pérez F, Delgado-Fernández M, Garcia-Lázaro M, Lozano F, Mohamed-Balghata MO; Sociedad Andaluza de Enfermedades Infecciosas. López-Cortés LF, et al. Among authors: lozano f. PLoS One. 2014 May 16;9(5):e97262. doi: 10.1371/journal.pone.0097262. eCollection 2014. PLoS One. 2014. PMID: 24836963 Free PMC article. Clinical Trial.
Lipid Changes in Virologically Suppressed HIV-Infected Patients Switching from any Antiretroviral Therapy to the Emtricitabine/Rilpivirine/Tenofovir Single Tablet: GeSida Study 8114.
Palacios R, Mayorga M, Pérez-Hernández IA, Rivero A, Arco AD, Lozano F, Santos J; GESIDA-8114-LIRA Study Group. Palacios R, et al. Among authors: lozano f. J Int Assoc Provid AIDS Care. 2016 May;15(3):189-93. doi: 10.1177/2325957416629785. Epub 2016 Feb 8. J Int Assoc Provid AIDS Care. 2016. PMID: 26858314 Free article.
Simplicity and efficacy of a once-daily antiretroviral regimen with didanosine, lamivudine, and efavirenz in naïve patients: the VESD study.
Santos J, Palacios R, López M, Gálvez MC, Lozano F, de la Torre J, Ríos MJ, López-Cortés LF, Rivero A, Torres-Tortosa M; Grupo Andaluz para el Estudio de las Enfermedades Infecciosas. Santos J, et al. Among authors: lozano f. HIV Clin Trials. 2005 Nov-Dec;6(6):320-8. doi: 10.1310/1XAE-BB0W-QN5R-AJGJ. HIV Clin Trials. 2005. PMID: 16566083 Clinical Trial.
Predictors of severe haematological toxicity secondary to pegylated interferon plus ribavirin treatment in HIV-HCV-coinfected patients.
Mira JA, López-Cortés LF, Merino D, Arizcorreta-Yarza A, Rivero A, Collado A, Ríos-Villegas MJ, González-Serrano M, Torres-Tortoso M, Macías J, Valera-Bestard B, Fernández-Fuertes E, Girón-González JA, Lozano F, Pineda JA; Grupo para el Estudio de las Hepatitis Viricas de la Sociedad Andaluza de Enfermedades Infecciosas. Mira JA, et al. Among authors: lozano f. Antivir Ther. 2007;12(8):1225-35. Antivir Ther. 2007. PMID: 18240862
550 results